Adaptimmune Therapeutics (ADAP) Stock Forecast & Price Target

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

$0.98

+0.08 (+8.92%)

(As of 04/19/2024 ET)

Adaptimmune Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Strong Sell
Based on 1 Analyst Ratings

Analysts' Consensus Price Target

$2.50
155.96% Upside

High Forecast	$4.00
Average Forecast	$2.50
Low Forecast	$1.00

Type	Current Forecast 4/20/23 to 4/19/24	1 Month Ago 3/21/23 to 3/20/24	3 Months Ago 1/20/23 to 1/20/24	1 Year Ago 4/20/22 to 4/20/23
Consensus Rating	Strong Sell	Hold	Hold	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	4 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$2.50	$4.65	$4.65	$6.12
Predicted Upside	155.96% Upside	331.41% Upside	331.41% Upside	257.69% Upside

Get Adaptimmune Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

ADAP Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ADAP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Adaptimmune Therapeutics Stock vs. The Competition

Type	Adaptimmune Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	1.00	2.68	2.49
Consensus Rating	Strong Sell	Moderate Buy	Hold
Predicted Upside	158.10% Upside	986.76% Upside	12.09% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date	Details
8/10/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$5.00 ➝ $4.00	+378.98%
8/10/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underweight ➝ Underweight	$2.00 ➝ $1.00	+17.65%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 07:53 PM ET.

ADAP Price Target - Frequently Asked Questions

What is Adaptimmune Therapeutics's consensus rating and price target?: According to the issued ratings of 1 analysts in the last year, the consensus rating for Adaptimmune Therapeutics stock is Sell based on the current 1 sell rating for ADAP. The average twelve-month price prediction for Adaptimmune Therapeutics is $2.50 with a high price target of $4.00 and a low price target of $1.00. Learn more on ADAP's analyst rating history.
Do Wall Street analysts like Adaptimmune Therapeutics more than its competitors?: Analysts like Adaptimmune Therapeutics less than other Medical companies. The consensus rating for Adaptimmune Therapeutics is Strong Sell while the average consensus rating for medical companies is Moderate Buy. Learn more on how ADAP compares to other companies.
Does Adaptimmune Therapeutics's stock price have much upside?: According to analysts, Adaptimmune Therapeutics's stock has a predicted upside of 195.85% based on their 12-month stock forecasts.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:ADAP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Adaptimmune Therapeutics (ADAP) Stock Forecast & Price Target

Adaptimmune Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

ADAP Analyst Ratings By Month

ADAP Price Targets by Month

Adaptimmune Therapeutics Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

ADAP Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info